Protocols
9 protocol(s) meet the specified criteria
Drug: PARAPLATIN
Protocol No.TitleStatus
A091101Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) –a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and NeckOpen
CALGB30605A Phase II Study of Induction Chemotherapy followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer Open (affiliates only)
EA8141A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial CarcinomaOpen
LCCC1330A Phase II study of carboplatin, paclitaxel and cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neckOpen
LCCC1612P53 mutational status and circulating free HPV DNA for the management of HPV-associated Oropharyngeal Squamous Cell Cancers Open
M14-360A Phase I Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)Open
NRG-BR003-CIRBA Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High- Risk Node-Negative Triple-Negative Invasive Breast CancerOpen
SGN19A-003A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplantOpen
WO30070A Phase Iii, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−Pd-L1 Antibody) In Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma Who Are Ineligible For Cisplatin-Based TherapyOpen